Arista Networks R&D decreased by 1.3% to $343.70M in Q1 2026 compared to the prior quarter. Year-over-year, this metric grew by 29.0%, from $266.40M to $343.70M. Over 4 years (FY 2021 to FY 2025), R&D shows an upward trend with a 20.5% CAGR.
Higher spending signals a commitment to innovation and future product launches, whereas significant cuts may indicate a shift toward short-term profitability.
Research and development expenses represent the costs incurred to discover new products, improve existing technologies,...
Highly comparable across pharmaceutical and medical device peers, where R&D intensity is a key metric for long-term valuation.
research_and_development| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $143.29M | $153.09M | $157.88M | $172.01M | $178.16M | $187.81M | $190.42M | $201.41M | $229.68M | $212.35M | $211.46M | $208.40M | $267.50M | $235.80M | $285.00M | $266.40M | $296.50M | $326.00M | $348.40M | $343.70M |
| QoQ Change | — | +6.8% | +3.1% | +8.9% | +3.6% | +5.4% | +1.4% | +5.8% | +14.0% | -7.5% | -0.4% | -1.4% | +28.4% | -11.9% | +20.9% | -6.5% | +11.3% | +9.9% | +6.9% | -1.3% |
| YoY Change | — | — | — | — | +24.3% | +22.7% | +20.6% | +17.1% | +28.9% | +13.1% | +11.0% | +3.5% | +16.5% | +11.0% | +34.8% | +27.8% | +10.8% | +38.3% | +22.2% | +29.0% |